← All trials
NCT04891965
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 27, 2020
- Primary completion
- Nov 30, 2022
- Completion date
- Feb 28, 2023
- First posted
- May 19, 2021
- Last posted
- Nov 19, 2021
- Enrollment
- 36
- Arms / groups
- 4 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Artugen Therapeutics USA, Inc.Lead sponsor
- Artugen Therapeutics USA, Inc.Study director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.